SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

SANA

Sana Biotechnology, Inc
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The Mayo Clinic partnership adds clinical validation and operational expertise, potentially accelerating SC451's path to trial. The equity investment signals confidence in Sana's platform, which could attract follow-on institutional interest. Monitor for IND filing and trial initiation as next catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.48
T+0 close · Apr 13, 2026 · via day close
Latest settled
+12.93%
T+60 · $3.93
Vs SPY
+4.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $3.48entry
  2. T+1 · 7mo ago −1.15%α −1.92% · $3.44
  3. T+5 · 7mo ago +6.32%α +4.93% · $3.70
  4. T+20 · 6mo ago +2.30%α −4.00% · $3.56
  5. T+60 · 4mo ago +12.93%α +4.41% · $3.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the development and clinical delivery of SC451, its investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. As part of the partnership, Mayo Clinic is making an equity investment in Sana, with an option for additional investment.

Key Facts

  • Sana and Mayo Clinic are collaborating to advance SC451, a stem-cell derived islet cell therapy for type 1 diabetes.
  • Collaboration focuses on optimizing clinical protocols, surgical techniques, and post-treatment care to support global scalability.
  • Mayo Clinic is making an equity investment in Sana, with an option for additional investment.
  • SC451 is designed to provide long-term glucose control without insulin or immunosuppression.
  • Sana expects to file an IND and initiate a Phase 1 trial for SC451 as early as 2026.

Financial Impact

Undisclosed equity investment by Mayo Clinic, with potential for additional capital

cashequitystrategic valuation

Risk Factors

  • SC451 development remains early-stage; IND acceptance and trial initiation are not guaranteed.
  • Clinical success of SC451 is uncertain despite promising early data.
  • Equity investment amount is undisclosed, limiting immediate financial impact assessment.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272888

Track record

12 reports on SANA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Viewing Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026